Homology Medicines Inc. shared its Q3 2023 results, showing a net loss of $33.0 million. The genetic medicines company has halted all of its programs due to the current financial climate and the expected clinical development timeline. This includes its HMI-103 gene editing candidate for the treatment of phenylketonuria (PKU). The company, which said it has enough cash to fund operations for a year, is now evaluating its strategic options and has retained TD Cowen as its strategic financial advisor.
A security researcher stumbled upon 600,000 sensitive files left in the open by data broker
Sensitive information was stored in an unencrypted database without password protection, leaving it vulnerable to unauthorized access. This lack of security measures can lead to
